| Cohen, Ezra |
NCT02769520: Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck |
|
|
| Active, not recruiting | 2 | 27 | US | Pembrolizumab, Keytruda | Assuntina Sacco, M.D., Merck Sharp & Dohme LLC | Squamous Cell Carcinoma of the Head and Neck | 04/25 | 04/26 | | |
NCT03795610: Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 15 | US | IPI-549 | Ezra Cohen, The V Foundation for Cancer Research | Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancer Stage III, HPV-Related Carcinoma, HPV-Related Malignancy, HPV-Related Squamous Cell Carcinoma | 06/23 | 06/23 | | |
KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC |
|
|
| Active, not recruiting | 2 | 63 | Europe, US | IO102-IO103 in combination with pembrolizumab | IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC | Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder | 01/24 | 11/24 | | |
| Recruiting | 2 | 26 | US | Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC | Erythroleukoplakia, Leukoplakia, Verrucous Oral Leukoplakia | 08/25 | 08/26 | | |
| Recruiting | 2 | 18 | US | Amivantamab | Trisha Wise-Draper | Salivary Gland Cancer | 08/24 | 08/28 | | |
| Recruiting | 2 | 81 | Europe, US, RoW | Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda | Flamingo Therapeutics NV | HNSCC | 05/25 | 05/26 | | |
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN |
|
|
| Withdrawn | 2 | 130 | Europe, US, RoW | RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab | Replimune Inc., Bristol-Myers Squibb | Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 03/26 | 06/26 | | |
NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies |
|
|
| Completed | 1/2 | 40 | US | IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy | ImmuneSensor Therapeutics Inc. | Solid Tumor, Adult | 09/23 | 09/23 | | |
NCT05153304: Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers |
|
|
| Withdrawn | 1/2 | 20 | US | personalized vaccine, Nivolumab, Opdivo | University of California, San Diego | Cancer of Gastrointestinal Tract | 06/26 | 06/27 | | |
NCT03991741: Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors |
|
|
| Recruiting | 1 | 24 | US | Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2 | Gregory Daniels, Immunotherapy Foundation | Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer | 08/24 | 08/26 | | |
NCT02418442: Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry |
|
|
| Recruiting | N/A | 20000 | Europe, Canada, US, RoW | | Duke University, Childhood Arthritis and Rheumatology Research Alliance | Rheumatic Joint Disease | 06/28 | 12/28 | | |
| Burgoyne, Adam M |
NCT03556384: Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) |
|
|
| Active, not recruiting | 2 | 23 | US | Temozolomide, TEMODAR® | Adam Burgoyne, MD, PhD | Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer | 06/25 | 06/26 | | |
| Recruiting | 2 | 100 | Europe, US | TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy | Boston Scientific Corporation, Biocompatibles UK Ltd | Hepatocellular Carcinoma | 06/27 | 06/27 | | |
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC |
|
|
| Recruiting | 2 | 30 | US | RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Replimune Inc., Roche Pharma AG | Hepatocellular Carcinoma | 12/27 | 07/28 | | |
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
|
|
| Recruiting | 1 | 321 | Europe, US | INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide | Inhibrx Biosciences, Inc | Colorectal Adenocarcinoma, Ewing Sarcoma | 06/26 | 12/26 | | |
NCT06710223: Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab |
|
|
| Not yet recruiting | 1 | 20 | NA | SD-101, nelitolimod, Cryotherapy, Tremelimumab, Durvalumab | University of California, San Diego, TriSalus Life Sciences | Hepatocellular Carcinoma | 06/27 | 06/27 | | |
NCT04145141: National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer |
|
|
| Recruiting | N/A | 500 | US | | National Cancer Institute (NCI) | Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma | 12/25 | 12/25 | | |
